DE69932313D1 - Wässerige flüssige zubereitungen - Google Patents

Wässerige flüssige zubereitungen

Info

Publication number
DE69932313D1
DE69932313D1 DE69932313T DE69932313T DE69932313D1 DE 69932313 D1 DE69932313 D1 DE 69932313D1 DE 69932313 T DE69932313 T DE 69932313T DE 69932313 T DE69932313 T DE 69932313T DE 69932313 D1 DE69932313 D1 DE 69932313D1
Authority
DE
Germany
Prior art keywords
gatifloxacin
aqueous liquid
liquid preparations
salt
sodium edetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69932313T
Other languages
English (en)
Other versions
DE69932313T2 (de
Inventor
Shinichi Yasueda
Katsuhiro Inada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Kyorin Pharmaceutical Co Ltd
Original Assignee
Senju Pharmaceutical Co Ltd
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16986030&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69932313(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Senju Pharmaceutical Co Ltd, Kyorin Pharmaceutical Co Ltd filed Critical Senju Pharmaceutical Co Ltd
Publication of DE69932313D1 publication Critical patent/DE69932313D1/de
Application granted granted Critical
Publication of DE69932313T2 publication Critical patent/DE69932313T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DE69932313T 1998-08-21 1999-08-20 Wässerige flüssige zubereitungen Expired - Lifetime DE69932313T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP23543298 1998-08-21
JP23543298 1998-08-21
PCT/JP1999/004483 WO2000010570A1 (fr) 1998-08-21 1999-08-20 Preparations liquides aqueuses

Publications (2)

Publication Number Publication Date
DE69932313D1 true DE69932313D1 (de) 2006-08-24
DE69932313T2 DE69932313T2 (de) 2007-07-19

Family

ID=16986030

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69932313T Expired - Lifetime DE69932313T2 (de) 1998-08-21 1999-08-20 Wässerige flüssige zubereitungen

Country Status (17)

Country Link
US (1) US6333045B1 (de)
EP (1) EP1025846B1 (de)
JP (1) JP5138128B2 (de)
KR (1) KR100595956B1 (de)
CN (1) CN1133432C (de)
AT (1) ATE332692T1 (de)
AU (1) AU761040B2 (de)
BR (1) BRPI9906735B8 (de)
CA (1) CA2307632C (de)
DE (1) DE69932313T2 (de)
DK (1) DK1025846T3 (de)
ES (1) ES2264266T3 (de)
HK (1) HK1029934A1 (de)
NZ (1) NZ504017A (de)
PT (1) PT1025846E (de)
TW (1) TW537895B (de)
WO (1) WO2000010570A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US6740664B2 (en) 1998-09-30 2004-05-25 Alcon, Inc. Methods for treating otic and ophthalmic infections
AU773218B2 (en) 1999-10-08 2004-05-20 Debiopharm International Sa Fab I inhibitors
AU2001230525A1 (en) * 2000-02-01 2001-08-14 Kyorin Pharmaceutical Co. Ltd. Sulfate salt of quinolonecarboxylic acid derivative and use thereof
DE60230934D1 (de) 2001-04-06 2009-03-05 Affinium Pharm Inc Fab-i-inhibitoren
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
WO2002089853A2 (en) * 2001-05-03 2002-11-14 Allergan, Inc. Compositions having enhanced pharmacokinetic characteristics
JP4859460B2 (ja) 2002-12-06 2012-01-25 アフィニウム ファーマシューティカルズ， インク． ヘテロ環化合物、その製造方法および治療におけるその使用
CA2519429C (en) 2003-03-17 2013-08-06 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
US20040202687A1 (en) * 2003-04-14 2004-10-14 Babu M.K. Manoj Ciprofloxacin formulations and methods of making and using the same
US20050085446A1 (en) * 2003-04-14 2005-04-21 Babu M.K. M. Fluoroquinolone formulations and methods of making and using the same
JP2005008625A (ja) * 2003-05-23 2005-01-13 Santen Pharmaceut Co Ltd キノロン系抗菌化合物を含有する点眼液
WO2007053131A2 (en) 2004-06-04 2007-05-10 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as antibiotic agents
EP1858506A2 (de) 2005-03-10 2007-11-28 3M Innovative Properties Company Verfahren zur behandlung von ohrinfektionen
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US8546423B2 (en) 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
CA2658506C (en) 2006-07-20 2016-01-26 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as fab 1 inhibitors
EP2078527A4 (de) * 2006-10-12 2011-12-21 Kyorin Seiyaku Kk Gatifloxacin enthaltende wässrige flüssige zubereitung
CN101547695B (zh) * 2006-10-12 2011-04-27 杏林制药株式会社 具有改进的加替沙星眼内渗透性的含水液体制剂
WO2008098374A1 (en) 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
CA2621616A1 (en) * 2007-02-19 2008-08-19 Alcon Research, Ltd. Topical gatifloxacin formulations
JP2008247828A (ja) * 2007-03-30 2008-10-16 Wakamoto Pharmaceut Co Ltd ラタノプロストを含有する水性医薬組成物。
JP5258331B2 (ja) * 2008-03-03 2013-08-07 ロート製薬株式会社 光安定性が改善されたニューキノロン系抗菌剤含有医薬組成物
MX2010010687A (es) * 2008-03-31 2011-02-24 Kyorin Seiyaku Kk Preparacion liquida acuosa que contiene gatifloxacina.
JP5535900B2 (ja) * 2008-03-31 2014-07-02 杏林製薬株式会社 ガチフロキサシン含有水性液剤、その製造方法、および、該水性液剤の低温保存および凍結融解時の沈殿生成を抑制する方法
WO2010042549A1 (en) 2008-10-07 2010-04-15 Mpex Pharmaceuticals, Inc. Inhalation of levofloxacin for reducing lung inflammation
NZ592717A (en) 2008-10-07 2013-03-28 Mpex Pharmaceuticals Inc Aerosol fluoroquinolone formulations for improved pharmacokinetics comprising levofloxacin or ofloxacin and a di- or trivalent cation
CA2752296C (en) * 2009-02-18 2018-09-11 Aradigm Corporation Ph-modulated formulations for pulmonary delivery
UA92423C2 (ru) * 2009-07-24 2010-10-25 Анатолій Альбертович Кузьмін Антибактериальная композиция
ES2739979T3 (es) 2009-09-04 2020-02-05 Horizon Orphan Llc Uso de levofloxacino en aerosol para el tratamiento de la fibrosis quística
MX353874B (es) 2012-03-26 2018-02-01 Santen Pharmaceutical Co Ltd Gotas para los ojos que contienen diquafosol.
WO2013190384A1 (en) 2012-06-19 2013-12-27 Affinium Pharmaceuticals, Inc. Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
MX2018010254A (es) 2016-02-26 2018-12-19 Debiopharm Int Sa Medicamento para el tratamiento de infecciones de pie diabetico.
JP6886322B2 (ja) * 2016-03-25 2021-06-16 興和株式会社 眼科用組成物
MX2019001633A (es) 2016-08-12 2019-09-18 Silk Tech Ltd Proteina derivada de la seda para el tratamiento de la inflamacion.
US20220062303A1 (en) 2020-08-26 2022-03-03 Somerset Therapeutics, Llc Prednisolone and moxifloxacin compositions and methods
US11510930B2 (en) 2020-08-26 2022-11-29 Somerset Therapeutics, Llc Gatifloxacin, prednisolone, and bromfenac compositions and methods
US11298315B2 (en) 2020-08-26 2022-04-12 Somerset Therapeutics, Llc. Triamcinolone and moxifloxacin compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU553415B2 (en) * 1983-09-19 1986-07-17 Abbott Japan Co., Ltd. 6-fluoro-1-4-dihydro-4-oxo-7-substituted piperazinyl- quinoline-3-carboxylic acids
JPH089597B2 (ja) 1986-01-21 1996-01-31 杏林製薬株式会社 選択毒性に優れた８‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法
JPH0696533B2 (ja) * 1987-01-14 1994-11-30 北陸製薬株式会社 キノロンカルボン酸の水性組成物
JP2549285B2 (ja) * 1987-02-02 1996-10-30 第一製薬株式会社 鼻用噴霧剤
JPH01258620A (ja) * 1988-04-08 1989-10-16 Dai Ichi Seiyaku Co Ltd 耳疾患用局所製剤
JP3996659B2 (ja) * 1995-10-25 2007-10-24 千寿製薬株式会社 血管新生抑制剤
JPH09124484A (ja) * 1995-10-27 1997-05-13 Schering Purau Kk 点眼剤
AU5342498A (en) * 1997-01-10 1998-08-03 Wakamoto Pharmaceutical Co., Ltd. Difluprednate-containing ophthalmic o/w emulsion composition

Also Published As

Publication number Publication date
CA2307632C (en) 2007-05-22
EP1025846A4 (de) 2004-12-29
KR20010031240A (ko) 2001-04-16
CA2307632A1 (en) 2000-03-02
AU5302699A (en) 2000-03-14
TW537895B (en) 2003-06-21
BRPI9906735B8 (pt) 2021-05-25
CN1275081A (zh) 2000-11-29
BRPI9906735B1 (pt) 2015-09-01
US6333045B1 (en) 2001-12-25
BR9906735A (pt) 2000-08-15
NZ504017A (en) 2001-09-28
EP1025846B1 (de) 2006-07-12
JP5138128B2 (ja) 2013-02-06
WO2000010570A1 (fr) 2000-03-02
PT1025846E (pt) 2006-10-31
ATE332692T1 (de) 2006-08-15
KR100595956B1 (ko) 2006-07-03
CN1133432C (zh) 2004-01-07
DK1025846T3 (da) 2006-11-06
HK1029934A1 (en) 2001-04-20
AU761040B2 (en) 2003-05-29
DE69932313T2 (de) 2007-07-19
EP1025846A1 (de) 2000-08-09
ES2264266T3 (es) 2006-12-16

Similar Documents

Publication Publication Date Title
ATE332692T1 (de) Wässerige flüssige zubereitungen
PE20010400A1 (es) Formulacion de sal comun y moxifloxacina
IL107533A0 (en) N'-substituted-n, n'-diacylhydrazines their preparation and their use as insecticides
CA2367505A1 (en) Coloring ceramics by way of ionic or complex-containing solutions
BR0313732A (pt) Compostos de pirimido tendo atividade antiproliferativa
NO308848B1 (no) Kromanforbindelse og farmasøytisk preparat som inneholder den
NO941937D0 (no) Sakarinderivater som inhiberer proteolytiske enzymer
BR0109650A (pt) 3-cianoquinolinas, 3-ciano-1,6-naftiridinas e 3-ciano-1,7-naftiridinas como inibidores da cinase proteìca
NO20031273L (no) Substituerte kanelsyreguanidiner, fremgangsmåte for deres fremstilling, deres anvendelse som legemiddel og legemiddel som inneholder de samme
FI95773B (fi) Menetelmä vesipitoisen, N-(3,4-dimetoksikinnamoyyli)antraniilihappoa sisältävän farmaseuttisen koostumuksen valmistamiseksi
DK1397681T3 (da) Fremgangsmåde til identificering af midler til behandling af diabetes
DK551885D0 (da) Middel og fremgangsmaade til efterbehandling af vasket vasketoej
ATE172721T1 (de) Aminosäurederivate und ihre verwendung als enkephalinase-inhibitoren
AU2001285944A1 (en) Fungicidal agent containing n-chlorotaurine and use thereof
DE60136064D1 (de) Wässrige flüssige preparation von pranoprofen
DE3778642D1 (de) Therapeutikum zur behandlung von magengeschwueren.
BR0206262B1 (pt) composiÇço antimicrobiana lÍquida, uso da mesma, e, mÉtodo de exterminar ou eliminar vÍrus ou esporos.
DE69815347D1 (de) Tetrahydrofuranderivate
DE59006292D1 (de) Wässrige Lösungen von Natriumsalzen des Trimercapto-s-triazins, deren Herstellung und Verwendung.
NO964905D0 (no) Substituerte benzendikarboksylsyre-diguanidiner, fremgangsmåte for deres fremstilling, deres anvendelse som medikament eller diagnostikum samt medikament inneholdende forbindelsen
DK174885A (da) Derivater af n-(3-phenylmethylthio-1-oxopropyl)-aminoeddikesyre i form af enantiomere eller blandinger, fremgangsmaade til fremstilling af forbindelserne og laegemiddel indeholdende disse
DK1318821T3 (da) Væske til hæmofiltrering
UA37377A (uk) Спосіб отримання мазі для лікування захворювань, які викликані внутрішньоклітинними інфекційними агентами
FR2600534B1 (fr) Procede pour empecher la coloration de preparations aqueuses de cefmenoxime.
UA43797A (uk) Ін'єкційна форма препарату, що проявляє протиішемічну активність

Legal Events

Date Code Title Description
8364 No opposition during term of opposition